Startups
Unicycive Therapeutics invent and develop medications that help kidney patients feel their best and enjoy the best possible quality of life.
Overview
Location
United States, California, Los Altos
Employees
11-50
Total raised
$6M
Founded date
2016
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 18
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 21, 2026 | Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission, March 25, 2027 PDUFA Date | Unicycive Therapeutics announces FDA acceptance of its resubmitted New Drug Application for oxylanthanum carbonate (OLC), with a PDUFA target action date of March 25, 2027. Unicycive Therapeutics advances OLC toward potential FDA approval f... |
| Oct 2, 2026 | Unicycive Therapeutics Appoints Meredith Manning to Board of Directors | Unicycive appoints biopharmaceutical commercialization executive Meredith Manning, M.B.A., to its Board of Directors as the Company advances OLC toward potential approval. Meredith Manning joins Unicycive’s Board, bringing more than 25 year... |
| Sep 30, 2026 | Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate | The resubmission package includes 12 months of OLC drug product stability data from the new manufacturing vendor Company anticipates FDA acceptance of the NDA within 30 days of resubmission; new assigned PDUFA date expected to be 6 months f... |
| Sep 1, 2026 | Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Unicycive Therapeutics CEO Shalabh Gupta, M.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15 at 11 a.m. ET. Unicycive Therapeutics will highlight its kidney disease pipeline at the H.C. Wainwr... |
| Aug 12, 2026 | Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update | Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing vendor FDA has assigned a facility inspection to third-party manufacturing ven... |
| Jul 1, 2026 | Unicycive Therapeutics Receives FDA Complete Response Letter for Oxylanthanum Carbonate NDA | Complete Response Letter relates to deficiencies previously identified at third-party manufacturing vendor Labeling discussions currently underway; latest communication received by the Company from FDA on June 29 regarding carton and contai... |
| Mar 17, 2026 | R1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatment | R1 Therapeutics is debuting with an oversubscribed $77.5 million series A financing aimed at advancing its first-in-class therapy for chronic kidney disease (CKD) patients on dialysis with high phosphate levels. The funding was co-led by Ab... |
| Sep 20, 2024 | Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing | Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the p... |
| Sep 16, 2024 | Life Sciences Virtual Investor Forum Agenda Announced for September 19th | Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda f... |
Show more
Reviews 0
FAQ about Unicycive Therapeutics
When was Unicycive Therapeutics founded?
Unicycive Therapeutics was founded in 2016.
How much funding has Unicycive Therapeutics raised?
Unicycive Therapeutics has raised $6M in total across 1 funding round.
What has the press written about Unicycive Therapeutics?
Parsers VC has collected 18 articles mentioning Unicycive Therapeutics, among them “Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission, March 25, 2027 PDUFA Date” (Oct 21, 2026) and “Unicycive Therapeutics Appoints Meredith Manning to Board of Directors” (Oct 2, 2026).
Is Unicycive Therapeutics still active?
Yes, Unicycive Therapeutics is active; its latest activity on Parsers VC dates from Nov 4, 2026.